HLA-A*02:01 MAGE-A4 を発現する固形腫瘍の参加者における CDR404 のヒトでの初の研究
HLA-A*02:01 MAGE-A4 発現固形腫瘍の参加者における CDR404 の安全性、忍容性、抗腫瘍活性を評価するフェーズ 1、ファーストインヒト研究
CDR404 is a highly potent and specific T-cell engaging bispecific and bivalent antibody designed for the treatment of cancers positive for the tumor-associated antigen melanoma-associated antigen 4 (MAGE-A4). This is a first-in-human study designed to evaluate the safety, tolerability, and preliminary anti-tumor activity of CDR404 in adult patients who have the appropriate germline human leukocyte antigen HLA-A*02:01 tissue marker and whose cancer is positive for MAGE-A4.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
The CDR404-001 Phase 1 study will enrol patients with locally advanced, unresectable or metastatic tumors expressing MAGE-A4, which include advanced solid tumors, and will be conducted in multiple phases:
- To identify the maximum tolerated dose (MTD) and pharmacologically effective dose range (PEDR) for CDR404
- To assess preliminary evidence of anti-tumor activity of CDR404
- To characterise the pharmacokinetics of CDR404
- To characterise the immunogenicity of CDR404
- To assess translational biomarkers
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
Oregon
-
Portland、Oregon、アメリカ、97213
- Providence Cancer Institute
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19106
- Pennsylvania Hospital
-
-
-
-
-
Glasgow、イギリス
- The Beatson West of Scotland Cancer Center
-
London、イギリス
- Guys and St Thomas' NHS Foundation Trust
-
-
London
-
Sutton、London、イギリス、SM2 5PT
- Royal Marsden Hospital
-
-
-
-
-
Milan、イタリア、20089
- Istituto Clinico Humanitas
-
Milan、イタリア、20141
- Isituto Europeo di Oncologia (IEO)
-
-
-
-
-
Barcelona、スペイン、08035
- Hospital Universitari Vall d'Hebron
-
Barcelona、スペイン、08908
- Institut Catala d'Oncologia, L'Hospitalet de Llobregat (ICO)
-
Madrid、スペイン、28041
- Hospital 12 de Octubre
-
Madrid、スペイン、28050
- START Madrid
-
Valencia、スペイン、46026
- Hospital Universitari i Politecnic La Fe
-
Valencia、スペイン、46026
- Instituto de Investigacion Sanitaria (INCLIVA)
-
-
-
-
-
Copenhagen、デンマーク、DK-2100
- Rigshospitalet
-
-
-
-
-
Antwerp、ベルギー、2650
- Universitair Ziekenhuis Antwerpen
-
Brussels、ベルギー、1070
- Institut Jules Bordet
-
Brussels、ベルギー、1200
- Cliniques Universitaires Saint-Luc, UCL Ouvain
-
Ghent、ベルギー、9000
- Universitair Ziekenhuis Gent
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Provision of written informed consent
- HLA-A*02:01 positive
- MAGE-A4 positive tumor
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) [ECOG PS] 0 or 1
- Selected advanced solid tumors
- Relapsed from, refractory to, or intolerant of standard therapy
- Measurable disease per RECIST v1.1
- Adequate organ function
- If applicable, must agree to use highly effective contraception
Exclusion Criteria:
- Symptomatic or untreated central nervous system metastasis
- Inadequate washout from prior anticancer therapy
- Significant ongoing toxicity from prior anticancer treatment
- Recent surgery
- Clinically significant cardiac disease
- Active infection requiring systemic antibiotic treatment
- Human immunodeficiency virus (HIV) at risk of acquired immunodeficiency syndrome (AIDS)-related outcomes
- Active hepatitis B virus (HBV) or hepatitis C virus (HBC)
- Ongoing treatment with systemic steroids or other immunosuppressive therapies
- Significant secondary malignancy
- History of chronic or recurrent active autoimmune disease requiring treatment
- Uncontrolled intercurrent illness
- Pregnancy or lactation.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:CDR404
Dose escalation |
IV infusions |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Presence of dose limiting toxicities (DLTs)
時間枠:From first dose to DLT period (21 days)
|
per Protocol |
From first dose to DLT period (21 days)
|
|
Incidence and severity of (serious) adverse events ([S]AEs)
時間枠:From first dose to 90 days after the last dose
|
AEs, SAEs |
From first dose to 90 days after the last dose
|
|
Anti-tumor response: Overall Response Rate (ORR)
時間枠:From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months
|
per RECIST 1.1 |
From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Disease control rate (DCR)
時間枠:From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months
|
per RECIST 1.1 |
From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months
|
|
Duration of response (DOR)
時間枠:From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months
|
per RECIST 1.1 |
From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months
|
|
Progression-free Survival (PFS)
時間枠:From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months
|
per RECIST 1.1 |
From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months
|
|
Overall Survival (OS)
時間枠:From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months
|
per RECIST 1.1 |
From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months
|
|
Maximum serum concentration of CDR404 (Cmax)
時間枠:At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
following single and multiple dose administration |
At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
|
Time to maximum serum concentration of CDR404 (Tmax)
時間枠:At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
following single and multiple dose administration |
At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
|
Trough serum concentration of CDR404 (Ctrough)
時間枠:At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
following single and multiple dose administration |
At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
|
Half-life of CDR404 (t1/2)
時間枠:At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
following single and multiple dose administration |
At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
|
Area under the CDR404 serum concentration over time curve (AUC0-T)
時間枠:At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
to the end of the dosing interval following single and multiple dose administration |
At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
|
Volume of CDR404 distribution (Vd)
時間枠:At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
following single and multiple dose administration |
At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
|
Average serum concentration of CDR404 (Cavg)
時間枠:At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
following single and multiple dose administration |
At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
|
Serum drug levels of CDR404 at steady state (CL)
時間枠:At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
following single and multiple dose administration |
At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
|
Accumulation ratio of CDR404 (Rac)
時間枠:At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
following single and multiple dose administration |
At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
|
Immunogenicity
時間枠:From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months
|
Incidence of detectable anti-CDR404 antibodies (ADAs) |
From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- CDR404-001
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。